Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

American Heart Association and Joint Commission launch new Comprehensive Heart Attack Center certification.

Death after TAVR: Heart failure, sudden cardiac arrest stand out as 2 leading causes

A majority of patient deaths within two years of TAVR can be linked to cardiovascular complications, according to new research published in JACC: Cardiovascular Interventions. Can follow-up care be improved to combat this trend? 

September 29, 2023
Tablet projecting metaphorical medical hologram

Bivalirudin linked to key benefit over heparin for NSTEMI patients undergoing PCI

The two anticoagulants are associated with similar mortality rates. However, a new meta-analysis in Circulation may have cardiologists favoring bivalirudin over heparin. 

September 26, 2023
Video of Prof. Dr. Ralph Stephan von Bardeleben explaining the latest details from key tricuspid valve trials.

What new tricuspid valve data tell us about the future of patient care

What are the latest updates on treating tricuspid regurgitation? We spoke with a leading researcher at ESC Congress 2023 to find out. 

September 26, 2023
durbin-ama-opioid. The American College of Cardiology (ACC) and American Heart Association (AHA) have published new guidelines focused on the diagnosis, treatment and management of patients with chronic coronary disease (CCD).

NOACs vs. VKAs in TAVR patients with new-onset AFib: New meta-analysis examines key differences

The biggest differences between the two treatment options were major bleeding events and all-cause mortality. There was no significant difference when it came to stroke risk. 

September 18, 2023
K-Clip Transvascular Tricuspid Repair System from Huihe Healthcare

Cardiologists use new annular clipping device for first time in US to treat severe tricuspid regurgitation

Interventional cardiologists with Henry Ford Health performed the historic procedure on an 85-year-old patient who had been experiencing worsening symptoms for a full year.

September 15, 2023
Interventional cardiologists performing PCI

PCI before TAVR fails to improve patient outcomes

“Our results beg the question of whether pre-TAVR baseline coronary angiography is even necessary,” researchers wrote in the American Journal of Cardiology.

September 15, 2023
LimFlow, a medical device company with locations in California and Paris, has gained approval from the U.S. Food and Drug Administration (FDA) for its LimFlow System for Transcatheter Arterialization of Deep Veins. The LimFlow System was designed to help reestablish blood flow in chronic limb-threatening ischemia (CLTI) patients who face a high risk of amputation and have no other endovascular or surgical options available to them.

FDA approves new minimally invasive CLTI treatment for ‘no-option’ patients at risk of amputation

The new device, the first of its kind to gain FDA approval, was designed for patients who have no other endovascular or surgical options available to them.

September 12, 2023
Private equity-backed cardiology group partners with additional healthcare investment firm.

High profits, consistent growth: Shockwave Medical seen as a ‘must-buy’ stock

Shockwave and two other healthcare companies in the cardiovascular health space are considered attractive options for investors looking to expand their portfolios. 

September 8, 2023

Around the web

Surgeons at NYU Langone Health successfully transplanted two genetically engineered pigs hearts into recently deceased humans in June and July.

Machine learning is playing a key role in predicting all major forms of drug cardiotoxicity, potentially helping reduce late-stage clinical trial failures.

Heart attack patients aged 65 and up stay hospitalized longer than those aged 65 or under—yet the seniors ring up significantly smaller bills per stay. The bad news is that the “savings” likely come in the form of fewer percutaneous coronary interventions (PCIs, aka angioplasties) to open blocked heart arteries nonsurgically.

Trimed Popup
Trimed Popup